Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- GSK Launches Tenozet, a First-Line Option for the Treatment of Chronic Hepatitis B
May 27, 2014
- DSP Ceases PIII Colorectal Cancer Trial for Anticancer Agent BBI608
May 27, 2014
- Concurrent Use Restrictions Lifted for 3 DPP-4 Inhibitor Products
May 27, 2014
- Chugai Concludes Deal with Roche for Chugai’s Antibody Engineering Technologies
May 27, 2014
- Daiichi Sankyo, US Research Institute to Collaborate in Developing Cardiovascular-Metabolic Disease Treatments
May 26, 2014
- 3 More SGLT-2 Inhibitors Make Japan Debuts to Trail Suglat
May 26, 2014
- Astellas Launches Anticancer Drug Xtandi Capsules in Japan
May 26, 2014
- Three Companies Including DSP Jointly Invest 845 Million Yen in Create Vaccine
May 26, 2014
- Teikoku Seiyaku Licenses Antiallergic Treatment from Uriach of Spain
May 26, 2014
- Foreign Drug Makers’ Japan Units Underperform Market Growth in 2013
May 23, 2014
- Blopress AG Rollout Won’t Coincide with June Listing: ASKA Pres.
May 23, 2014
- 5 of 17 Pharmacy Chains Settle April-June Delivery Prices via Qol-Led Open Tender
May 23, 2014
- Teva Pharma Japan to Postpone NHI Price Listing of All Generics Including Valsartan in June
May 23, 2014
- JPMA Code Committee to Discuss Actions against Kyowa Kirin, Novartis over Improper Involvement in Clinical Trials
May 22, 2014
- Takeda’s UC, CD Treatment Entyvio Approved in US
May 22, 2014
- EPS Did Nothing Wrong in Data Verifications for VART Study Probe: Pres.
May 21, 2014
- AZ to Highlight Global Data to Push Forxiga: Primary Care Head
May 21, 2014
- Towa Wins Japan’s 1st Approval for Viagra Generic
May 21, 2014
- Improper Staffer Involvement in 4 More Japan CML Programs: Novartis
May 20, 2014
- Medipal Holdings Sets 2,253 Billion Yen Goal for FY2016 Ethical Drug Wholesaling Sales
May 20, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…